CIK 0001516551
- Non-accelerated filer
- Smaller reporting company
Skye Bioscience, Inc.
Sign in to watch- Ticker
- SKYE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- NV
- Entity type
- Operating
- EIN
- 450692882
- Phone
- +1 858-410-0266
- Business address
- 11250 EL CAMINO REAL, SUITE 100, SAN DIEGO, CA, 92130
- Former names
- Emerald Bioscience, Inc., Nemus Bioscience, Inc., LOAD GUARD LOGISTICS, INC., LOAD GUARD TRANSPORTATION, INC.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $613,506
- in 6 filings
Net −$613,506. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-02-06 | Twitty Christopher Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +150,000 | 150,000 | ||
| 2026-02-06 | Charych Deborah H. Director | Grant or award · Stock Option (Right to Buy) | +35,000 | 35,000 | ||
| 2026-02-06 | Jenkins Annalisa Director | Grant or award · Stock Option (Right to Buy) | +35,000 | 35,000 | ||
| 2026-02-06 | Diep Tuan Tu Chief Development Officer | Grant or award · Stock Option (Right to Buy) | +125,000 | 125,000 | ||
| 2026-02-06 | Arora Puneet S. Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +125,000 | 125,000 | ||
| 2026-02-06 | DHILLON PUNIT Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +280,000 | 280,000 | ||
| 2025-08-22 | Schwab Andrew J. Director | Sale | −163,979 | $3.42 | $561K | 1,457,064 |
| 2025-08-22 | Schwab Andrew J. Director | Sale | −6,470 | $3.42 | $22K | 57,493 |
| 2025-08-22 | 5AM Partners VII, LLC 10% owner | Sale | −163,979 | $3.42 | $561K | 1,457,064 |
| 2025-08-22 | 5AM Partners VII, LLC 10% owner | Sale | −6,470 | $3.42 | $22K | 57,493 |
| 2025-08-21 | Schwab Andrew J. Director | Sale | −58,642 | $3.57 | $209K | 1,621,043 |
| 2025-08-21 | Schwab Andrew J. Director | Sale | −2,314 | $3.57 | $8K | 63,963 |
| 2025-08-21 | 5AM Partners VII, LLC 10% owner | Sale | −58,642 | $3.57 | $209K | 1,621,043 |
| 2025-08-21 | 5AM Partners VII, LLC 10% owner | Sale | −2,314 | $3.57 | $8K | 63,963 |
| 2025-02-24 | Schwab Andrew J. Director | Grant or award · Stock Option (Right to Buy) | +35,000 | 35,000 | ||
| 2025-02-24 | ARSENAULT KAITLYN Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +150,000 | 150,000 | ||
| 2025-02-24 | Jenkins Annalisa Director | Grant or award · Stock Option (Right to Buy) | +35,000 | 35,000 | ||
| 2025-02-24 | Grayson Paul A. Director | Grant or award · Stock Option (Right to Buy) | +135,000 | 135,000 | ||
| 2025-02-24 | Smith Karen L. Director | Grant or award · Stock Option (Right to Buy) | +35,000 | 35,000 | ||
| 2025-02-24 | DHILLON PUNIT Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +250,000 | 250,000 |
Page 5 of 15 · 292 trades